MEDISCA issues U.S. Patent 10,420,705 for planetary mixers adapter
Category: #health  By Pankaj Singh  Date: 2020-02-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

MEDISCA issues U.S. Patent 10,420,705 for planetary mixers adapter

MEDISCA Inc., a global leader in the pharmaceutical compounding industry, has recently announced the issuance of U.S. Patent 10,420,705 for an adapter used in planetary mixers. This adapter caters to customers who seek homogeneity and faster mixing times, the same as that being offered by rotation-revolution mixers. In the pharmaceutical setting, this final mixed product could be placed in the same dispenser used by pharmacists in their regular compounding activities.

The company is making consistent strides in the field of pharmaceutical compounding and seeking innovations, which is reflected by the company’s recent addition of Patent 10,420,705 to its existing global patent portfolio.

In the recent past, the company also filed patents on the uses and functionalities of the MAZ™, namely United States Patents 10,420,705 and 10,231,903. MAZ™ is a well-known brand of a high-performing planetary mixer, which has been adopted in large number of compounding pharmaceutical settings, worldwide. The brand is currently made available exclusively by MEDISCA.

According to MEDISCA’s Senior Director, Panagiota Danopoulos, the company swiftly identifies customers’ issues while dealing with specific business process, and promptly delivers innovative solutions to them for easy workflow. The company is dedicated to offering the highest level of quality ingredients used for medications as well as ensuring the safety and effectiveness of the compounding process to customers it serves.

MEDISCA possesses several intellectual property rights and these portfolios have been expanding globally across Canada, the United States, and other key commercial markets. The company intends to continue placing extra focus on providing top class pharmaceutical compounding ingredients while delivering innovative products and services, in order to avoid any adverse claims.

Additionally, the company is planning to make significant investments in research and development activities, marketing products, issuing patents, as well as increasing trademark portfolios to promote its high-quality products and services on a global scale.

Source credit:

https://apnews.com/Business%20Wire/f0247025465a4d009671a6e8d9c78d4c



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Sirnaomics reveals dose administration of 1st patient in STP705 trial
Sirnaomics reveals dose administration of 1st patient in STP705 trial
By Pankaj Singh

Sirnaomics, Inc., a clinical-stage biopharmaceutical company, has recently announced the dose administration of the 1st patient in a Phase 2a clinical trial of STP705. STP705 is a lead drug candidate develop...

Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
By Pankaj Singh

The pharma giant Pfizer Inc. has reportedly declared that the U.S. Food and Drug Administration (US FDA) has approved the sNDA (supplemental New Drug Application) for XALKORI® (crizotinib) for the treatment of chil...

JCB unites with ACI Worldwide to boost merchant acquiring capabilities
JCB unites with ACI Worldwide to boost merchant acquiring capabilities
By Pankaj Singh

JCB International, a credit card company, has reportedly partnered with ACI Worldwide, a payment system company, to increase merchant acquiring capabilities across the globe.

The To...